Beruflich Dokumente
Kultur Dokumente
Key words: mediastinum – mediastinal neoplasms – germ cell tumor – tumor markers
TREATMENT
The treatments used in the 48 patients with mediastinal GCTs
are summarized in Fig. 1. All patients who received chemo-
therapy initially or postoperatively were treated with a regimen
containing cisplatin. The chemotherapy regimen used in each
Table 2. Relapse-free patients with preoperative elevated serum tumor marker levels
Patient Age (years) Preoperative Histology Viable cells Postoperative Prognosis (years)
treatment treatment
1 24 Chemo Non-seminoma Negative High-dose 6.2, alive, NED
2 16 Chemo Non-seminoma Negative None 6.8, alive, NED
3 17 None Non-seminoma – Chemo 0.7, dead, NED
Chemo, conventional chemotherapy; Viable cells, viable cells present in the resected specimen; High-dose, high-dose chemo-
therapy with PBSCT; NED, no evidence of disease.
Table 4. Operative mortality and morbidity and HCG, plays a crucial role in defining the outlook
(6,15,16,32,33). In the present study, patients with preoperative
Mortality and morbidity No. of patients (%) normal tumor marker levels had significantly better survival
Operative death 1 (3%) than those with preoperative elevated tumor marker levels. Sur-
Postoperative morbidity 4 (13%) gical resection for patients whose markers have not normalized
with chemotherapy is usually futile (4,6,34–36). Dulmet and
Wound infection 2
colleagues also stated that normalizing serum tumor marker
Empyema 1
levels before surgical resection was a significant favorable
DIC 1 prognostic factor (7). On the other hand, Vuky and associates
found a tendency for shorter survival in patients with elevated
DIC, disseminated intravascular coagulation. and increasing tumor markers compared to patients with nor-
Patient Age Initial treatment Histology Viable cells Postoperative Prognosis (years)
(years) treatment
1 24 Chemo Non-seminoma Negative High-dose 6.2, alive, NED
2 27 High-dose Non-seminoma Positive None 1.9, dead, WD
3 21 High-dose Non-seminoma Positive None 0.8, dead, WD
Chemo, conventional chemotherapy; High-dose, high-dose chemotherapy with peripheral blood stem cell transplantation;
Viable cells, viable cells present in the resected specimen; NED, no evidence of disease; WD, with disease.
Jpn J Clin Oncol 2004;34(7) 391
GCTs (7–9,13,15,29,31,40–42). The Southeastern Cancer prognosis. However, the clinical implications and indications
Study Group reported excellent sustained remissions with ini- of surgical resection must be investigated further. Additional-
tial chemotherapy in all patients with mediastinal seminomas ly, more appropriate and effective therapeutic strategies are
(19). In our study, five patients with seminoma, who received needed in the treatment of patients with mediastinal GCT to
chemotherapy followed by surgery, all had CR without any achieve better survival rates.
viable cells in the resected specimen. Motzer and colleagues
proposed that close observation without surgery is possible for
seminoma patients with a post-chemotherapy residual tumor of References
3 cm or less in diameter because none of the patients with a 1. Hainsworth JD, Greco FA. Extragonadal germ cell tumors and unrecog-
residual tumor of this size had viable cells in the resected spec- nized germ cell tumors. Semin Oncol 1992;19:119–27.
2. Fine G, Smith RW, Pachter MR. Primary extragenital choriocarcinoma in
imen (43). In the present study, two patients with pure semi- male subject. Case report and review of the literature. Am J Med 1962;32:
marrow transplantation in first-line therapy for patients with poor-risk the significance of histology with particular reference to differentiated
germ cell tumors. J Natl Cancer Inst 1993;85:1828–35. (mature) teratoma. Br J Cancer 1984;50:601–9.
22. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. 35. Motzer RJ, Bosl GJ. Chemotherapy for germ cell tumors. Urol Clin North
High-dose carboplatin, etoposide, and cyclophosphamide for patients with Am 1987;14:389–98.
refractory germ cell tumors: treatment results and prognostic factors for 36. Motzer RJ, Geller NL, Tan CC, Herr H, Morse M, Fair W, et al. Salvage
survival and toxicity. J Clin Oncol 1996;14:1098–105. chemotherapy for patients with germ cell tumors. The Memorial Sloan-
23. Shepherd FA, Ginsberg R, Patterson GA, Feld R, Goss PE, Pearson FG, et Kettering Cancer Center experience (1979–1989). Cancer 1991;67:1305–
al. Is there ever a role for salvage operations in limited small-cell lung 10.
cancer? J Thorac Cardiovasc Surg 1991;101:196–200. 37. Vuky J, Bains M, Bacik J, Higgins G, Bajorin DF, Mazumdar M, et al.
24. Asamura H, Tsuchiya R, Goya T, Kondo H, Naruke T, Saijo N, et al. Role of postchemotherapy adjunctive surgery in the management of
Malignant germ cell tumor of the mediastinum: a multimodality therapeu- patients with nonseminoma arising from the mediastinum. J Clin Oncol
tic approach. Surg Today 1994;24:137–141. 2001;19:682–8.
25. Goss PE, Schwertfeger L, Blackstein ME, Iscoe NA, Ginsberg RJ, 38. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, et
Simpson WJ, et al. Extragonadal germ cell tumors. A 14-year Toronto al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol